Active Biotech - Interim report Jan-Jun 2004
| Source:
Active Biotech
Active Biotech
- Partnership agreement for laquinimod (SAIK-MS) signed with Teva Pharmaceutical Industries
- TTS CD3 for lung cancer progressing according to plan
- Collaboration agreement signed with Strathmann Biotec for the production of TTS
- Patient study for TASQ prostate-cancer project to commence during the second half of the year
- Phase I study for the SLE project planned to start during the third quarter
- Net revenues SEK 30.4 M (0.1)
- Loss after net financial items SEK 77.4 M (loss: 139.3)
- Loss per share for the period amounted to SEK 2.29 (loss: 7.63)
- Loss after tax SEK 77.4 M (loss: 139.3)
Attachments